BioAge Labs (NASDAQ:BIOA) Earns Buy Rating from BTIG Research

BioAge Labs (NASDAQ:BIOA)‘s stock had its “buy” rating restated by research analysts at BTIG Research in a note issued to investors on Tuesday, Benzinga reports. They presently have a $40.00 target price on the stock. BTIG Research’s price target would suggest a potential upside of 324.18% from the company’s previous close.

Other equities analysts have also recently issued reports about the company. Wall Street Zen cut BioAge Labs from a “sell” rating to a “strong sell” rating in a report on Saturday. Needham & Company LLC reduced their target price on BioAge Labs from $50.00 to $35.00 and set a “buy” rating on the stock in a report on Friday, July 31st. Jefferies Financial Group set a $21.00 price target on BioAge Labs in a research report on Friday, July 31st. Roth Capital reaffirmed a “buy” rating and issued a $25.00 price target on shares of BioAge Labs in a research note on Friday, July 31st. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioAge Labs in a research report on Tuesday, July 21st. Six analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $36.57.

BioAge Labs Trading Down 1.7%

Shares of NASDAQ:BIOA traded down $0.16 on Tuesday, reaching $9.43. 87,498 shares of the company’s stock were exchanged, compared to its average volume of 693,825. BioAge Labs has a twelve month low of $4.68 and a twelve month high of $25.95. The company has a fifty day moving average of $16.19 and a 200-day moving average of $17.74. The company has a market capitalization of $432.81 million, a price-to-earnings ratio of -3.97 and a beta of 0.94.

BioAge Labs (NASDAQ:BIOA) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($0.58) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.65) by $0.07. The business had revenue of $2.45 million during the quarter. BioAge Labs had a negative return on equity of 28.99% and a negative net margin of 912.26%. As a group, equities research analysts forecast that BioAge Labs will post -2.45 EPS for the current fiscal year.

Institutional Trading of BioAge Labs

Hedge funds have recently made changes to their positions in the company. Legal & General Group Plc acquired a new stake in BioAge Labs during the 2nd quarter worth approximately $84,000. Russell Investments Group Ltd. bought a new position in shares of BioAge Labs during the 3rd quarter worth about $27,000. State of Wyoming acquired a new position in BioAge Labs during the second quarter worth $154,000. The Manufacturers Life Insurance Company bought a new stake in BioAge Labs during the 2nd quarter worth approximately $234,000. Finally, Bank of Nova Scotia purchased a new position in shares of BioAge Labs during the first quarter valued at approximately $180,000.

About BioAge Labs

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.